Browse CCNA2

Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus Cytoplasm Note=Exclusively nuclear during interphase (PubMed:1312467). Detected in the nucleus and the cytoplasm at prophase (PubMed:1312467). Cytoplasmic when associated with SCAPER (PubMed:17698606).
Domain PF02984 Cyclin
PF00134 Cyclin
PF16500 N-terminal region of cyclin_N
Function

Cyclin which controls both the G1/S and the G2/M transition phases of the cell cycle. Functions through the formation of specific serine/threonine protein kinase holoenzyme complexes with the cyclin-dependent protein kinases CDK1 or CDK2. The cyclin subunit confers the substrate specificity of these complexes and differentially interacts with and activates CDK1 and CDK2 throughout the cell cycle.

> Gene Ontology
 
Biological Process GO:0000075 cell cycle checkpoint
GO:0000077 DNA damage checkpoint
GO:0000079 regulation of cyclin-dependent protein serine/threonine kinase activity
GO:0000086 G2/M transition of mitotic cell cycle
GO:0000302 response to reactive oxygen species
GO:0001666 response to hypoxia
GO:0006979 response to oxidative stress
GO:0007067 mitotic nuclear division
GO:0007093 mitotic cell cycle checkpoint
GO:0007095 mitotic G2 DNA damage checkpoint
GO:0007265 Ras protein signal transduction
GO:0007346 regulation of mitotic cell cycle
GO:0007423 sensory organ development
GO:0010035 response to inorganic substance
GO:0010389 regulation of G2/M transition of mitotic cell cycle
GO:0010948 negative regulation of cell cycle process
GO:0010972 negative regulation of G2/M transition of mitotic cell cycle
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031570 DNA integrity checkpoint
GO:0031572 G2 DNA damage checkpoint
GO:0032355 response to estradiol
GO:0033762 response to glucagon
GO:0034599 cellular response to oxidative stress
GO:0034614 cellular response to reactive oxygen species
GO:0034698 response to gonadotropin
GO:0034699 response to luteinizing hormone
GO:0036119 response to platelet-derived growth factor
GO:0036120 cellular response to platelet-derived growth factor stimulus
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0042220 response to cocaine
GO:0043279 response to alkaloid
GO:0043434 response to peptide hormone
GO:0043583 ear development
GO:0044320 cellular response to leptin stimulus
GO:0044321 response to leptin
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044773 mitotic DNA damage checkpoint
GO:0044774 mitotic DNA integrity checkpoint
GO:0044818 mitotic G2/M transition checkpoint
GO:0044839 cell cycle G2/M phase transition
GO:0045786 negative regulation of cell cycle
GO:0045930 negative regulation of mitotic cell cycle
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048839 inner ear development
GO:0070482 response to oxygen levels
GO:0071241 cellular response to inorganic substance
GO:0071312 cellular response to alkaloid
GO:0071314 cellular response to cocaine
GO:0071371 cellular response to gonadotropin stimulus
GO:0071373 cellular response to luteinizing hormone stimulus
GO:0071375 cellular response to peptide hormone stimulus
GO:0071392 cellular response to estradiol stimulus
GO:0071396 cellular response to lipid
GO:0071407 cellular response to organic cyclic compound
GO:0071417 cellular response to organonitrogen compound
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071731 response to nitric oxide
GO:0071732 cellular response to nitric oxide
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0090102 cochlea development
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901987 regulation of cell cycle phase transition
GO:1901988 negative regulation of cell cycle phase transition
GO:1901990 regulation of mitotic cell cycle phase transition
GO:1901991 negative regulation of mitotic cell cycle phase transition
GO:1902170 cellular response to reactive nitrogen species
GO:1902749 regulation of cell cycle G2/M phase transition
GO:1902750 negative regulation of cell cycle G2/M phase transition
GO:1904029 regulation of cyclin-dependent protein kinase activity
GO:1990314 cellular response to insulin-like growth factor stimulus
Molecular Function -
Cellular Component GO:0001939 female pronucleus
GO:0001940 male pronucleus
GO:0045120 pronucleus
> KEGG and Reactome Pathway
 
KEGG hsa04110 Cell cycle
hsa04152 AMPK signaling pathway
hsa04914 Progesterone-mediated oocyte maturation
Reactome R-HSA-174143: APC/C-mediated degradation of cell cycle proteins
R-HSA-176409: APC/C
R-HSA-179419: APC
R-HSA-176814: Activation of APC/C and APC/C
R-HSA-174184: Cdc20
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-2559583: Cellular Senescence
R-HSA-2262752: Cellular responses to stress
R-HSA-69273: Cyclin A/B1 associated events during G2/M transition
R-HSA-69656: Cyclin A
R-HSA-69202: Cyclin E associated events during G1/S transition
R-HSA-2559586: DNA Damage/Telomere Stress Induced Senescence
R-HSA-5693532: DNA Double-Strand Break Repair
R-HSA-73894: DNA Repair
R-HSA-69306: DNA Replication
R-HSA-5688426: Deubiquitination
R-HSA-1538133: G0 and Early G1
R-HSA-69615: G1/S DNA Damage Checkpoints
R-HSA-69206: G1/S Transition
R-HSA-68911: G2 Phase
R-HSA-69275: G2/M Transition
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-5693567: HDR through Homologous Recombination (HR) or Single Strand Annealing (SSA)
R-HSA-5693538: Homology Directed Repair
R-HSA-392499: Metabolism of proteins
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-453274: Mitotic G2-G2/M phases
R-HSA-68949: Orc1 removal from chromatin
R-HSA-170145: Phosphorylation of proteins involved in the G2/M transition by Cyclin A
R-HSA-597592: Post-translational protein modification
R-HSA-5693607: Processing of DNA double-strand break ends
R-HSA-176408: Regulation of APC/C activators between G1/S and early anaphase
R-HSA-69304: Regulation of DNA replication
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804756: Regulation of TP53 Activity through Phosphorylation
R-HSA-6804757: Regulation of TP53 Degradation
R-HSA-6806003: Regulation of TP53 Expression and Degradation
R-HSA-453276: Regulation of mitotic cell cycle
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-187577: SCF(Skp2)-mediated degradation of p27/p21
R-HSA-2559582: Senescence-Associated Secretory Phenotype (SASP)
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804116: TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-5689880: Ub-specific processing proteases
R-HSA-69563: p53-Dependent G1 DNA Damage Response
R-HSA-69580: p53-Dependent G1/S DNA damage checkpoint
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CCNA2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CCNA2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.12; FDR: 0.03500 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CCNA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1470.665
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.090.955
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1890.876
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.2930.567
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2270.869
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3850.837
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.2310.543
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4690.735
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1250.929
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3610.662
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7080.571
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5251.67e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CCNA2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCNA2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCNA2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCNA2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCNA2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CCNA2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CCNA2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCCNA2
Namecyclin A2
Aliases CCNA; cyclin-A; Cyclin-A2
Chromosomal Location4q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CCNA2 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting CCNA2.
ID Name Drug Type Targets #Targets
DB020914-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-YlamineSmall MoleculeCCNA2, CDK22
DB024076-O-Cyclohexylmethyl GuanineSmall MoleculeCCNA2, CDK22
DB02833[4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-AmineSmall MoleculeCCNA2, CDK22
DB029154-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamineSmall MoleculeCCNA2, CDK22
DB068444-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB06944N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamideSmall MoleculeCCNA2, CDK22
DB069482-ANILINO-6-CYCLOHEXYLMETHOXYPURINESmall MoleculeCCNA2, CDK22
DB07126O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINESmall MoleculeCCNA2, CDK22
DB07137(2S)-N-[(3Z)-5-CYCLOPROPYL-3H-PYRAZOL-3-YLIDENE]-2-[4-(2-OXOIMIDAZOLIDIN-1-YL)PHENYL]PROPANAMIDESmall MoleculeCCNA2, CDK22
DB07164N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB072036-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINESmall MoleculeCCNA2, CDK22
DB074715-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDESmall MoleculeCCNA2, CDK22
DB075334-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075344-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075384-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB075394-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACIDSmall MoleculeCCNA2, CDK22
DB07562N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINESmall MoleculeCCNA2, CDK22
DB076884-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB078521-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACIDSmall MoleculeCCNA2, CDK22
DB081784-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB081824-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amineSmall MoleculeCCNA2, CDK22
DB08218HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUMSmall MoleculeCCNA2, CDK22
DB082194-METHYL-5-{(2E)-2-[(4-MORPHOLIN-4-YLPHENYL)IMINO]-2,5-DIHYDROPYRIMIDIN-4-YL}-1,3-THIAZOL-2-AMINESmall MoleculeCCNA2, CDK22
DB082336-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINESmall MoleculeCCNA2, CDK22
DB082414-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDESmall MoleculeCCNA2, CDK22
DB082483-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDESmall MoleculeCCNA2, CDK22
DB08285(2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-olSmall MoleculeCCNA2, CDK22
DB083093-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OLSmall MoleculeCCNA2, CDK22
DB083551-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acidSmall MoleculeCCNA2, CDK22
DB08463(2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-olSmall MoleculeCCNA2, CDK22
DB085271-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDESmall MoleculeCCNA2, CDK22
DB085724-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDESmall MoleculeCCNA2, CDK22
DB086949-amino-5-(2-aminopyrimidin-4-yl)pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidin-4-olSmall MoleculeCCNA2, CDK22